Latest News
Nektar Therapeutics presents rezpegaldesleukin data at 2026 AAD Annual Meeting
30 March 2026 - US biopharmaceutical company Nektar Therapeutics (Nasdaq:NKTR) reported on Saturday that it had showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.Data from ...
Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis
30 March 2026 - US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Saturday that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse ...
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
30 March 2026 - Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Saturday reported results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to ...
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
30 March 2026 - New Zealand-based soft tissue repair specialist Aroa Biosurgery Limited announced on Sunday completion of its randomised controlled trial (RCT) evaluating Symphony in patients with diabetic foot ulcers, with a preliminary read-out ind...
Novartis to acquire Excellergy in USD2bn deal
...